On August 25, 2025, Stoke Therapeutics, Inc. and Biogen Inc. announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress (IEC). The data included three-year results from open-label extension (OLE) studies, which demonstrated the potential for disease modification in patients with Dravet syndrome.
These long-term data showed durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior, observed on top of standard anti-seizure medicines. Additionally, substantial improvements in overall seizure burden and seizure-free days were observed with ongoing treatment, reinforcing the drug's therapeutic potential.
Zorevunersen, an investigational antisense oligonucleotide, is currently being evaluated in the global pivotal EMPEROR Phase 3 study. The positive long-term effects observed to date further support the design of the EMPEROR study and highlight zorevunersen's potential to address the underlying genetic cause of Dravet syndrome, a severe developmental and epileptic encephalopathy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.